Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Good news for tirzepatide users: a new meta-analysis finds the popular weight-loss drug isn't linked to atrial fibrillation in people with overweight or obesity. Researchers did spot modestly higher odds of arrhythmias overall — though event rates were low and findings are considered exploratory. No red flags yet, but experts say more dedicated cardiac monitoring in future trials would help clarify the picture.
Good news for tirzepatide users worried about heart rhythm: a new meta-analysis published in the Journal of the American Heart Association finds no clear link between the GLP-1/GIP receptor agonist and atrial fibrillation (AF) or atrial arrhythmia in adults with overweight or obesity. The analysis pooled data from 10 randomized controlled trials involving over 6,500 patients.
That said, tirzepatide was associated with modestly higher odds of any arrhythmia compared to placebo — though event rates remained low and the evidence was rated as moderate certainty. Researchers caution that arrhythmias weren't prespecified endpoints in most trials, making these findings exploratory rather than definitive.
By the Numbers
Why it matters: As tirzepatide becomes one of the most widely prescribed obesity treatments, understanding its cardiac safety profile is critical. While no AF signal emerged, the arrhythmia finding underscores the need for future trials to include cardiac rhythm as a prespecified endpoint.
